BioBijou Expands Orders for ECM 'CELIVION'... Targeting Second-Half Sales Growth with Grand Launch in September

BioBijou is set to drive sales growth in the second half of the year with the ECM (extracellular matrix) skin revitalizer 'CELIVION.' Product orders are increasing, particularly among domestic dermatology and plastic surgery clinics, and the company plans to accelerate its market outreach through a large-scale launch event.

On August 25, BioBijou announced that it will host the 'CELIVION Grand Launching Ceremony' on September 10, inviting approximately 150 domestic and international medical professionals.

The event aims to enhance CELIVION's brand recognition and expand touchpoints with domestic medical professionals. The program will include lectures, panel discussions, and celebratory performances. The lineup features a lecture on hADM by Director Lee Kyungrak of Bereni Fore Clinic and a filler lecture by Director Kim Geonwoo of Selenic Clinic.

CELIVION is an acellular allogeneic dermis-based ECM skin revitalizer manufactured by Orthotech. BioBijou has secured exclusive domestic distribution rights for the product and began full-fledged domestic sales at the end of May this year.

The company highlights as its main strength that CELIVION advances beyond conventional beauty-focused ECM skin boosters by focusing on skin tissue recovery and creating a regenerative environment.

In particular, the product employs the low-temperature 'allo-PELT' process to preserve the ECM structure and key proteins, thereby enhancing tissue recovery and regeneration efficiency. With a high collagen content and an ultra-fine uniform particle design, the focus is on ensuring both the durability of regenerative effects and consistent results from procedures.

To boost CELIVION sales, BioBijou is actively pursuing branding and making inroads with clinics and hospitals. The strategy is to quickly expand CELIVION's market penetration by leveraging its existing network of dermatology and plastic surgery clinics established through previous supply of skin boosters and fillers.

The company explained that clinics and hospitals already receiving the product are placing additional orders, and inquiries from new institutions interested in supply are also on the rise. This has led to growing interest in CELIVION's potential to become a major new product driving performance in the second half of the year.

The increase in medical tourism to Korea by foreign visitors is also cited as a favorable factor, as rising demand for dermatology visits and aesthetic procedures by international tourists is expanding the overall market.

BioBijou plans to gradually pursue overseas market entry after establishing CELIVION's presence in the domestic market. The company plans to expand global sales channels for its ECM skin revitalizer by utilizing its overseas network built through its skin booster and filler business.

The company also expressed high expectations, noting that its product portfolio is expanding as CELIVION and other new products are added to its existing medical cosmetic business.

Joonho Yang, CEO of BioBijou, stated, "In addition to our core medical cosmetic, skin booster, and filler businesses, the rapidly growing ECM skin revitalizer market has led to a significant increase in corporate performance compared to last year. We will further strengthen our competitiveness in domestic and overseas markets through continuous new product development and expansion of our product portfolio."

This content was produced with the assistance of AI translation services.